A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LAE102 Injection in Healthy and Overweight/Obese Subjects
Latest Information Update: 27 Jun 2025
At a glance
Most Recent Events
- 23 Jun 2025 Results presented in the Laekna Media Release.
- 23 Jun 2025 According to Laekna, Inc media release, result form this trial were presented at the 85th scientific sessions of the American Diabetes Association (ADA).
- 09 Apr 2025 Protocol amended with addition of part C multiple dose ascending and addition of From Day 1 to Day91 for multiple dose part timeframe for primary endpoint